These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine.
    Author: Whittle HC, Rowland MG, Mann GF, Lamb WH, Lewis RA.
    Journal: Lancet; 1984 Oct 13; 2(8407):834-7. PubMed ID: 6148572.
    Abstract:
    Five different vaccination schedules were used to immunise Gambian infants aged 4-6 months against measles with the attenuated Edmonston-Zagreb strain of virus, which has a history of passage in human diploid cells. Vaccine aerosol given either by mask in a dose of 3500 or 7000 plaque-forming units (PFU) or from a plastic bag at a dose of 7000 PFU raised haemagglutinin-inhibiting or plaque-inhibiting measles antibody 16-24 weeks after vaccination to a titre of 1 in 8 or greater in all but 3 of the 51 children so vaccinated. All 21 infants given 11 400 PFU of vaccine intradermally in two divided doses and the 21 given 39 000 PFU of the virus subcutaneously also had satisfactory levels of measles antibody 16 weeks after vaccination. None of the vaccinated children had clinical evidence of measles in the 12 to 17 months after vaccination. The Edmonston-Zagreb vaccine, given subcutaneously or by other routes at 4-6 months, may be useful in preventing measles in infants in African cities, where 15-30% of children have measles before they are 9 months old, which is the recommended age for immunisation with the chick-cell-adapted strains of measles virus. 5 different vaccination schedules were used to immunize Gambian infants aged 4-6 months against measles with the attenuated Edmonston-Zagreb strain of virus, which has a history of passage in human diploid cells. Vaccine aerosol given either by mask in a dose of 3500 or 7000 plaque-forming units (PDUs) or from a plastic bag at a dose of 7000 PFU raised hemagglutinin-inhibiting or plaque-inhibiting measles antibody 16-24 weeks after vaccination to a titer of 1 in 8 greater in all but 3 of 51 children so vaccinated. All 21 infants given 11,400 PFU of vaccine intradermally in 2 divided doses and the 21 given 39,000 PFU of the virus subcutaneously also had satisfactory levels of measles antibody 16 weeks after vaccination. None of the vaccinated children had clinical evidence of measles in the 12-17 months after vaccination. The Edmonston-Zagreb vaccine, given subcutaneously or by other routes at 4-6 months, may be useful in preventing measles in infants in African cities,where 15-30% of children have measles before 9 months of age, which is the recommended age for immunization with the chick-cell-adapted strains of measles virus.
    [Abstract] [Full Text] [Related] [New Search]